GSK advances in Pfizer consumer health auction as Reckitt quits

NEW YORK/LONDON (Reuters) – GlaxoSmithKline has pulled ahead in a race to buy Pfizer’s consumer healthcare business, which the U.S. drugmaker believes could be worth as much as $20 billion, after its main rival Reckitt Benckiser quit the auction.


Source: Reuters

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>